ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,326Medicare Part D Prescriptions Filled, Including Refills

Rank: 50 out of 487

$417K Total Retail Price of All Prescriptions

Rank: 72 out of 487

400 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
20% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Idaho
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 400 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

12% of this provider’s 400 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

1% of this provider’s 7,494 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Idaho
LEVOTHYROXINE SODIUM 481 423 1 1
SIMVASTATIN 351 345 2 4
HYDROCODONE-ACETAMINOPHEN 295 256 S3 3 3
LISINOPRIL 291 257 4 5
OMEPRAZOLE 289 249 5 2
AMLODIPINE BESYLATE 280 278 6 6
LOSARTAN POTASSIUM 247 242 7 16
PRAVASTATIN SODIUM 221 205 8 20
METFORMIN HCL 195 175 9 8
ZOLPIDEM TARTRATE 189 176 10 14
FENOFIBRATE 160 160 11 61
RANITIDINE HCL 137 117 12 39
POTASSIUM CHLORIDE 133 125 13 10
TRIAMTERENE-HCTZ 131 115 14 49
CITALOPRAM HBR 127 125 15 12
METOPROLOL SUCCINATE 124 123 16 15
RAMIPRIL 122 119 17 121
ALENDRONATE SODIUM 105 99 18 27
FLUTICASONE PROPIONATE 103 76 19 33
ZETIA 101 101 20 104
TAMSULOSIN HCL 99 93 21 25
MELOXICAM 90 81 22 26
ALLOPURINOL 82 66 23 29
METOPROLOL TARTRATE 82 82 23 17
FLUOXETINE HCL 81 74 25 28
GABAPENTIN 81 60 25 13
WARFARIN SODIUM 79 69 27 11
ATENOLOL 77 68 28 23
PAROXETINE HCL 74 59 29 51
TORSEMIDE 73 63 30 138
FUROSEMIDE 72 59 31 7
METFORMIN HCL ER 70 70 32 31
SPIRONOLACTONE-HCTZ 70 65 32 159
TRAZODONE HCL 69 55 34 22
CRESTOR 65 62 35 42
RISPERIDONE 62 62 36 58
TRAMADOL HCL 62 55 36 19
SERTRALINE HCL 62 60 36 21
GLIMEPIRIDE 59 59 39 35
ADVAIR DISKUS 59 58 39 46
BUPROPION XL 58 39 41 97
KLOR-CON M20 57 53 42 83
CARVEDILOL 54 53 43 32
POLYETHYLENE GLYCOL 3350 51 49 44 56
ROPINIROLE HCL 51 39 44 60
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 12, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.